Stephens Consulting, LLC Nuvalent, Inc. Transaction History
Stephens Consulting, LLC
- $399 Billion
- Q1 2025
A detailed history of Stephens Consulting, LLC transactions in Nuvalent, Inc. stock. As of the latest transaction made, Stephens Consulting, LLC holds 10 shares of NUVL stock, worth $716. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10Holding current value
$716% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding NUVL
# of Institutions
232Shares Held
57.8MCall Options Held
834KPut Options Held
490K-
Deerfield Management Company, L.P. (Series C) New York, NY18MShares$1.29 Billion34.87% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY5.36MShares$384 Million16.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.5MShares$322 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.02MShares$217 Million0.01% of portfolio
-
Perceptive Advisors LLC New York, NY2.62MShares$188 Million6.84% of portfolio
About Nuvalent, Inc.
- Ticker NUVL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,977,800
- Market Cap $3.08B
- Description
- Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...